HF-10
- Generic Name
- HF-10
Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 7
- Registration Number
- NCT03259425
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Phase 1
Completed
- Conditions
- Squamous Cell Carcinoma, SkinCarcinoma of the BreastMalignant MelanomaRefractory Head and Neck Cancer
- Interventions
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT01017185
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath